Symbol
| MAP2K1
| contributors: mct/pgu - updated : 14-04-2017
|
HGNC name
| mitogen-activated protein kinase kinase 1
|
HGNC id
| 6840
|
corresponding disease(s)
|
CFC3
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
| germinal mutation
|  
|  
|  
|
missense mutation in CFC | tumoral
| somatic mutation
|  
|  
|  
|
in melanomas | constitutional
| somatic mutation
|  
|  
|  
|
are a common cause of extracranial arteriovenous malformation (AVM) | tumoral
| somatic mutation
|  
|  
|  
|
in BRAF V600E-negative Langerhans cell histiocytosis | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| is a promising prognostic biomarker candidate correlated to response to platinum based chemotherapy in ovarian cancer | Therapy target
|
System | Type | Disorder | Pubmed |
miscelleaneous | vascular | | |
. MEK1 inhibitors, which are approved to treat several forms of cancer, are potential therapeutic agents for individuals with extracranial Arteriovenous malformation (AVM) | diabete | type 2 | | |
MAP2K1 signaling pathway could be a novel therapeutic target for novel antidiabetic agents |
| | |
| The null mutation of the mouse Mek1 gene by insertional mutagenesis was recessive lethal, and homozygous mutant embryos died at 10.5 days of gestation. Histopathologic analysis revealed a marked decrease of vascular endothelial cells in the labyrinthine region, resulting in reduced vascularization of the placenta. Failure to establish a functional placenta was considered a likely cause of embryonic death. |